Celgene

Committed to improving the lives of patients worldwide

 

About

Celgene, a Bristol-Myers Squibb Company, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialisation of innovative therapies for the treatment of cancer and inflammatory diseases, through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

 

Committed to improving the lives of patients worldwide

At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myelomamyelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.

 

Products: POMALYST®

Delivering new options for multiple myeloma patients

Multiple myeloma is a cancer of a type of immune cell called a plasma cell that affects nearly half a million people around the world. Despite significant progress in treatment over the past decade, this blood cancer remains challenging due to its cyclical and progressive nature, as well as its ability to mutate and adapt over time.

Celgene is a pioneer in multiple myeloma research and has discovered and is developing an extensive portfolio of therapies in this area. As a leader, whose very foundations were built upon helping patients with this incurable disease, we remain committed to delivering new and better options for these patients through our deep scientific and technical expertise.

 

Connect

For more information, please visit www.celgene.com.au or www.bms.com/au

Celgene Pty Ltd.
ABN 42 118 998 771
Level 15, 60 City Road
Southbank, VIC, 3006, Australia.
Tel: 1800 CELGENE (1800 235 4363)